Risk factors for red blood cell alloimmunization in patients with hematologic malignancy.
Pakthipa PattarakosolNattarat LorucharoenPhandee WatanaboonyongcharoenPonlapat RojnuckarinPublished in: Transfusion medicine (Oxford, England) (2024)
The prevalence of RBC alloimmunization in the patients with hematologic malignancy was 4.8%. The alloimmunization rate of the AML subgroup was higher than those of other hematologic malignancies. The detection of autoantibodies and the AML diagnosis were identified as potential risk factors for RBC alloimmunization.